Sudan ebolavirus (SUDV) (SUDV)

Sudan ebolavirus (SUDV) is a highly pathogenic virus within the Filoviridae family and is the causative agent of Sudan virus disease (SVD), a severe form of viral hemorrhagic fever (World Health Organization, 2023). It is an enveloped, negative-sense single-stranded RNA virus whose genome encodes seven distinct proteins, including the Glycoprotein (GP), Nucleoprotein (NP), and RNA-dependent RNA polymerase (L protein) (NCBI Taxonomy, 2024). The viral Glycoprotein is the primary target for therapeutic development as it mediates host cell attachment and membrane fusion (PubMed, PMID: 30651215). Other therapeutic strategies target the L protein to inhibit viral replication or the VP35 protein to counteract viral suppression of the host's innate immune response (UniProt, P11310). SUDV is transmitted through direct contact with infected fluids and is associated with high mortality rates, often exceeding 50% (CDC, 2022). Current drug development efforts include monoclonal antibody cocktails like MBP134 and small-molecule antivirals such as Remdesivir, which aim to neutralize the virus or block its replication cycle (Science Translational Medicine, 2019). Therapeutic challenges include the rapid progression of the disease and the requirement for high-containment (BSL-4) facilities for research (Nature, 2016). Clinical management primarily involves supportive care, as no specific antiviral has been universally approved for SUDV, though several candidates are in clinical trials (The Lancet Infectious Diseases, 2023).

Other names

Sudan virusSUDVSEBOVEbola SudanSudan Ebola virus

Inhibition of viral RNA-dependent RNA polymerase (L protein) to prevent genome replication (PubMed, PMID: 27016777); Neutralization of the viral Glycoprotein (GP) to block attachment and fusion with host cell membranes (Science Translational Medicine, 2019); Competitive inhibition of viral RNA synthesis (Antiviral Research, 2014).